SELLAS Life Sciences Group (SLS) Study result summary
Event summary combining transcript, slides, and related documents.
Study result summary
17 Nov, 2026Trial design
Global, randomized, open-label Phase III REGAL enrolled 126 AML patients in CR2 or later/CRp2 or later after salvage therapy who could not undergo allogeneic transplant; patients were randomized 1:1 to GPS maintenance monotherapy or investigator-selected BAT.
Overall survival was the primary endpoint; GPS is an investigational, off-the-shelf WT1-targeting vaccine designed to stimulate CD4+ and CD8+ T-cell responses.
Efficacy results
REGAL met its primary endpoint, with a 41% reduction in risk of death for GPS versus BAT (HR 0.59; two-sided P=0.035); the primary analysis followed the prespecified 80-death threshold and statistical plan.
Median overall survival was 24.0 months with GPS versus 14.7 months with BAT.
Safety and control context
GPS was generally well tolerated, with no new safety signals; treatment-related events were predominantly grade 1/2 and included transient injection-site reactions.
BAT options included observation, hypomethylating agents, venetoclax and/or low-dose cytarabine; BAT median OS exceeded historical real-world benchmarks of ~8-10 months.
Treatment arms were balanced on prognostic stratification factors, and few patients proceeded to stem cell transplantation, equally distributed between arms.
Latest events from SELLAS Life Sciences Group
- GPS met REGAL’s OS endpoint as SLS009 advances across AML settings.SLS
Corporate presentation - GPS advances in Phase 3 AML as SLS009 delivers promising Phase 2 results.SLS
Corporate presentation - REGAL topline results are expected in November as SLS009 advances, with $134.7 million in cash.SLS
Q3 2026 - Net loss rose to $18.0M in H1 2026; cash reached $138.3M as clinical programs advanced.SLS
Q2 2026 - All proposals passed amid strong financial growth and clinical progress toward pivotal milestones.SLS
AGM 2026 - Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum - GPS and SLS009 advance as late-stage, first-in-class AML therapies with pivotal data imminent.SLS
R&D Day 2025